HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Pustular syphilide — Clinical Guidelines

Overview

Pustular syphilide encompasses a spectrum of severe pustular dermatoses characterized by widespread sterile pustules, systemic inflammation, and potential life-threatening complications. These conditions include generalized pustular psoriasis and subcorneal pustular dermatosis, often requiring prompt and aggressive management. 1 2

Diagnosis

Presence of widespread sterile pustules

Signs of systemic inflammation (fever, leukocytosis)

Histological confirmation showing subcorneal pustules

Consider genetic testing in pediatric cases for early recognition 2

Management

First-line treatments:

- IL-36 inhibitors (specific dosing not detailed) - IL-17 inhibitors (specific dosing not detailed)

Adjunctive treatments:

- TNF-α inhibitors (lower response rates compared to IL-36 and IL-17 inhibitors) - IL-23 inhibitors (lower response rates compared to IL-36 and IL-17 inhibitors) - For refractory cases, consider biologics targeting specific cytokines 1

Specific case management:

- Acrodermatitis continua of Hallopeau: etretinate may be beneficial 5 - Subcorneal pustular dermatosis: dapsone showed improvement in canine models, suggesting potential off-label use in humans 6

Special Populations

Pediatrics: Early recognition and genetic testing are crucial for timely intervention 2

Comorbidities: Pulmonary capillary leak syndrome may occur, warranting close monitoring of respiratory function and cytokine involvement 3

Key Recommendations

Initiate treatment with IL-36 inhibitors or IL-17 inhibitors for generalized pustular psoriasis due to higher response rates 1 (Evidence: Strong)

Monitor for systemic complications, particularly in pediatric patients and those with suspected cytokine-driven pulmonary involvement 3 2 (Evidence: Moderate)

Consider off-label use of etretinate for acrodermatitis continua of Hallopeau refractory to conventional therapy 5 (Evidence: Weak)

References

1 Chen BL, Liu QW, Dong XW, Bai YP. Biologics for generalized pustular psoriasis: a systematic review and single-arm meta-analysis. Frontiers in immunology 2024. link 2 Posso-De Los Rios CJ, Pope E. New insights into pustular dermatoses in pediatric patients. Journal of the American Academy of Dermatology 2014. link 3 McGregor JM, Barker JN, MacDonald DM. Pulmonary capillary leak syndrome complicating generalized pustular psoriasis: possible role of cytokines. The British journal of dermatology 1991. link 4 Lin RY, Schwartz RA, Lambert WC. Subcorneal pustular dermatosis with polyarthritis. Cutis 1986. link 5 Pearson LH, Allen BS, Smith JG. Acrodermatitis continua of Hallopeau: treatment with etretinate and review of relapsing pustular eruptions of the hands and feet. Journal of the American Academy of Dermatology 1984. link80157-7) 6 McKeever PJ, Dahl MV. A disease in dogs resembling human subcorneal pustular dermatosis. Journal of the American Veterinary Medical Association 1977. link

Pustular syphilide